Ethylene

Ethylene

SCHEMBL466154

C=C.C=C.C=C.NP(N)(N)=S

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL628124 0.87
Bromide SCHEMBL31522771 0.80
Hydrochloric Acid SCHEMBL28504855 0.80
Propene SCHEMBL11415440 0.71
Benzene SCHEMBL28417806 0.71 TP53 (0.33)
Phosphoramidic Acid SCHEMBL29992750 0.64 CA2 (0.36)
SCHEMBL3069011 0.62
SCHEMBL7660252 0.62
SCHEMBL11428327 0.62
Ethylene SCHEMBL22582369 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4086250-B1 MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2024-12-11 EP claimed
US-20240374569-A1 HDAC3 INHIBITORS FOR THE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS AND LANGERHANS CELL SARCOMA HENRY FORD HEALTH SYSTEM 2024-11-14 US claimed
WO-2023049798-A1 HDAC3 INHIBITORS FOR THE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS AND LANGERHANS CELL SARCOMA HENRY FORD HEALTH SYSTEM (US) 2023-03-30 WO claimed
US-20200289662-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE LEGOCHEM BIOSCIENCES, INC. (KR) 2020-09-17 US claimed
US-10583197-B2 Antibody-active agent conjugates and methods of use LEGOCHEM BIOSCIENCES, INC. (KR) 2020-03-10 US claimed
CN-110167586-A Duplication-defective arenavirus particle and three-segment arenavirus particles as cancer vaccine 霍欧奇帕生物科技有限公司 2019-08-23 CN claimed
CN-110099682-A Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof 杭州多禧生物科技有限公司 2019-08-06 CN claimed
CN-104411332-B Human antibody in conjunction with VEGFR2 索伦托治疗有限公司 2018-11-23 CN claimed
CN-108136038-A Conjugates comprising peptide groups and methods related thereto 乐高化学生物科学股份有限公司 2018-06-08 CN claimed
CN-105273368-B A kind of expandable PET resin and its production and use 华东理工大学 2018-04-03 CN claimed
CN-1479630-A Methods of inducing cancer cell death and tumor regression Q 2004-03-03 CN claimed
EP-1351946-A2 MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT ICOS CORPORATION (US) 2003-10-15 EP claimed
US-20020165218-A1 Materials and methods to potentiate cancer treatment LUITPOLD PHARMACEUTICALS, INC. 2002-11-07 US claimed
CN-1364084-A Method of inducing cancer cell death and tumor regression SCHERING CORP (US) 2002-08-14 CN claimed
WO-2002020500-A2 MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT ICOS CORPORATION (US) 2002-03-14 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
CN-1255164-A Modified antisense nucleotides complementary to human Ha-ras gene segments HOECHST MARION & ROUSSEL DEUTS (DE) 2000-05-31 CN claimed
EP-0316440-B1 System and method for providing localized Mössbauer absorption in an organic medium MILLS RANDELL L (US) 1996-01-03 EP claimed
EP-0419890-A2 Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method AMERICAN CYANAMID COMPANY (US) 1991-04-03 EP claimed
EP-0019167-B1 MEDICINAL PREPARATION FOR THE TREATMENT OF CARCINOMA AND PROCESS FOR PREPARING IT Limburg, Hans, Dr. (DE) 1983-10-12 EP claimed